Home › Chronic Myeloid Leukemia › Illinois
Chronic Myeloid Leukemia clinical trials in Illinois
7 studies for Chronic Myeloid Leukemia are looking for participants at sites in Illinois.
Cities in Illinois
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
- Ann and Robert H Lurie Childs Hosp, Chicago
RecruitingPhase 2
Ages 1 to 18 · All sexes · Updated Nov 10, 2026 · NCT07354074Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- OSF Saint Anthony's Health Center, Alton
- Advocate Outpatient Center - Aurora, Aurora
- Advocate Good Shepherd Hospital, Barrington
- and 52 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Nov 4, 2026 · NCT05334069Study of Olverembatinib (HQP1351) in Patients With CML-CP
- Ascentage Investigative Site #1055, Chicago
- Ascentage Investigative Site #1095, Decatur
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT06423911A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Northwestern Memorial Hospital, Chicago
- Rush University Medical Center, Chicago
- University of Illinois at Chicago, Chicago
- and 3 more
RecruitingObservational study
All ages · All sexes · Updated Jul 6, 2026 · NCT01351545A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
- Northwestern Medicine, Chicago
RecruitingPhase 1
Ages 12 and older · All sexes · Updated Mar 16, 2026 · NCT06994676Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
- The University of Chicago, Chicago
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Dec 29, 2025 · NCT03326310ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
- University of Chicago Comprehensive Cancer Center, Chicago
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2025 · NCT03595917From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.